The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to provide a more substantial loss in body mass and benefit metabolic markers, pa… Read More